Qamar J. Khan
Expertise in
9
conditions

Dr. Qamar J. Khan

Hematology
2650 Shawnee Mission Parkway, 
Westwood, KS 
On Staff At
Accepting New Patients
Offers Telehealth
40 Years of Experience
Expertise in
9
conditions
2650 Shawnee Mission Parkway, 
Westwood, KS 

Overview

Qamar Khan is a Hematologist in Westwood, Kansas. Dr. Khan has been practicing medicine for over 40 years is highly rated in 9 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Breast Cancer in Men, and Angiosarcoma. Dr. Khan is currently accepting new patients.

His clinical research consists of co-authoring 42 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

King Edward Medical College, Doctor Of Medicine, 1986

Residency

Yale New Haven Health Bridgeport Hospital, Internal Medicine, 1997

Specialties

Hematology

Licenses

Internal Medicine in KS

Board Certifications

American Board Of Internal Medicine, Hematology - 2005

Fellowships

University of Kansas School of Medicine, Hematology and Oncology, 2004

Hospital Affiliations

Olathe Medical Center
University Of Kansas Hospital

Languages Spoken

English
Urdu

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
SelectHealth
  • HMO
  • POS
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Richard and Annette Bloch Cancer Care Pavilion
2650 Shawnee Mission Parkway, Westwood, KS 66205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

42 Total Publications

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 14, 2025
Similar Doctors
Abdulraheem Yacoub
Expertise in
51
conditions
Dr. Abdulraheem Yacoub
Hematology
Expertise in
51
conditions
Dr. Abdulraheem Yacoub
Hematology

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (1.2 miles away)
913-588-1227
Experience:
23+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdulraheem Yacoub is a Hematologist in Fairway, Kansas. Dr. Yacoub has been practicing medicine for over 23 years is highly rated in 51 conditions, according to our data. His top areas of expertise are Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Yacoub is currently accepting new patients.

Leyla O. Shune
Expertise in
32
conditions
Dr. Leyla O. Shune
Hematology
Expertise in
32
conditions
Dr. Leyla O. Shune
Hematology

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (1.2 miles away)
913-588-1227
Experience:
22+ years
Languages Spoken:
English, Somali, Swahili, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Leyla Shune is a Hematologist in Fairway, Kansas. Dr. Shune has been practicing medicine for over 22 years is highly rated in 32 conditions, according to our data. Her top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shune is currently accepting new patients.

Sunil H. Abhyankar
Expertise in
40
conditions
Dr. Sunil H. Abhyankar
Hematology
Expertise in
40
conditions
Dr. Sunil H. Abhyankar
Hematology

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (1.2 miles away)
913-588-1227
Experience:
42+ years
Languages Spoken:
English, Hindi, Marathi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunil Abhyankar is a Hematologist in Fairway, Kansas. Dr. Abhyankar has been practicing medicine for over 42 years is highly rated in 40 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Abhyankar is currently accepting new patients.

Frequently Asked Questions about Dr. Qamar J. Khan

How do I make an appointment with Dr. Qamar J. Khan?

You can book an appointment with Dr. Qamar J. Khan by calling their office at 913-588-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Qamar J. Khan a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Qamar J. Khan is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Qamar J. Khan specialize in?

While Dr. Qamar J. Khan is a Hematology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Breast Cancer in Men. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Qamar J. Khan participate in research or clinical trials?

Yes. Dr. Qamar J. Khan has published 42 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Qamar J. Khan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Qamar J. Khan accept my insurance?

Dr. Qamar J. Khan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-588-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khan's expertise for a condition
ConditionClose
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile